Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome.
Lopez
J S
JS
de Smet
M D
MD
Masur
H
H
Mueller
B U
BU
Pizzo
P A
PA
Nussenblatt
R B
RB
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D015822:Eye Infections, Parasitic / Q000150:complications / Q000188:drug therapy; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D014126:Toxoplasmosis, Ocular / Q000150:complications / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D053626:Atovaquone